DEFENCE THERAPEUTICS INC
Commented by Armin Schulz on May 7th, 2025 | 07:10 CEST
Evotec's AI gold mine, Defence Therapeutics' billion-dollar markets, Novo Nordisk's diet revolution: How investors are profiting
The healthcare industry is undergoing radical change. Algorithms are accelerating drug discovery by years, billions are being poured into personalized therapies, and biotech stocks are celebrating on the stock markets. But this time, it is not just short-lived hype – the next era of medicine will be shaped by companies merging technology and biology. While AI-based platforms identify drug candidates in record time, pioneers are pushing ahead with groundbreaking approaches in oncology, immunology, and metabolic diseases. Three names stand out: Evotec, Defence Therapeutics, and Novo Nordisk.
Read
Commented by Fabian Lorenz on May 1st, 2025 | 07:10 CEST
A bombshell at Nel ASA! Buying opportunity for Bayer and Defence Therapeutics shares?
A bombshell at Nel ASA. The hydrogen specialist has reported its first quarter results: revenue and order intake are down, while the Company is sliding deep into the red. Will new major shareholder Samsung bring about a turnaround? Defence Therapeutics is a hot rebound candidate with takeover speculation. The biotech company is consistently pushing ahead with the monetization of its technology and has found a strong partner. The decline in the share price in recent months offers opportunities. A lot of negative news is certainly already priced into Bayer's share price, but is that enough to buy the stock? Yes, according to analysts.
Read
Commented by Stefan Feulner on April 29th, 2025 | 07:15 CEST
Coinbase, Defence Therapeutics, Palantir – Forward-looking decisions
The current trading week promises to be super exciting. In addition to possible surprise posts from Donald Trump on his Truth Social platform regarding punitive tariffs, the highlight of the reporting season is coming up. Around 800 companies will provide insights into their annual reports over the next few days, including heavyweights such as Coca-Cola and Mastercard, as well as tech giants Microsoft, Meta Platforms, and Qualcomm.
Read
Commented by André Will-Laudien on April 22nd, 2025 | 07:20 CEST
This is the post-Easter opportunity! Evotec, Bayer, BioNTech, and Defence Therapeutics in focus
Donald Trump snubs his international partners, insults prominent Americans, and withdraws long-standing funding commitments to Harvard. Who would have thought? The new US administration is turning out to be an unpredictable fragmentation bomb that could hit anyone. Economic policy resembles a game of hot and cold when stability is needed. On the stock market, investors are trying to price in old tariffs, no tariffs, and new tariffs - every day brings a fresh bouquet of announced measures. There has hardly been a similarly volatile period in recent years, but Donald Trump is not interested in stock market prices. For the overvalued high-tech sector, this is a welcome opportunity to take profits. The biotech sector could finally take off were it not for the sharp rise in interest rates. The only thing that can help now is a case-by-case assessment of investment opportunities.
Read
Commented by Armin Schulz on April 17th, 2025 | 08:10 CEST
Blockbuster or takeover fever? Why Novo Nordisk, Defence Therapeutics, and Pfizer are now attracting attention
The biotech and pharmaceutical industry resembles a billion-dollar chessboard! A single move – whether a takeover or drug approval – can double share prices in a matter of hours or completely reshape entire markets. While investors are still marveling at the spectacular rally of Theratechnologies, which opened with a gap up and then soared another 45% in a single day, or analyzing the Phase-3 explosion at Corcept, the next players are already lining up for the big coup. Because in this arena, it is not just about who develops the next blockbuster but also who buys, sells, or forms strategic alliances. There are three names to have on your radar: Novo Nordisk, Defence Therapeutics, and Pfizer. Each of these companies is pursuing its own master plan.
Read
Commented by Nico Popp on April 15th, 2025 | 09:50 CEST
Bayer, BioNTech, Defence Therapeutics: The new biotech reality opens up opportunities
The pharmaceutical sector is exempt from US tariffs. But does that mean everything will be okay for the industry? During the German Biotech Days in Heidelberg, which took place last week, market experts were cautious. Following the layoffs at the US Food and Drug Administration (FDA), there are concerns among pharmaceutical companies and biotech firms that the US could lose its leading position in research and development. According to the researchers at the conference, Europe could step into the breach under certain conditions – however, partnerships with other regions remain crucial for continued progress.
Read
Commented by Fabian Lorenz on April 10th, 2025 | 07:30 CEST
A buying opportunity in the price horror? Novo Nordisk, BioNTech, and Defence Therapeutics!
For Novo Nordisk shareholders, who have been spoiled by price gains, the current nightmare shows no sign of ending. The notion that pharmaceutical stocks are a safe haven in turbulent times is only partially true at the moment. Novo Nordisk shares are trading at their lowest level since 2022. A buying opportunity? Yes, analysts believe, but the Trump-induced chaos is not going away anytime soon. For those looking to invest in relative strength, there is currently no getting around Defence Therapeutics. The biotech company is not affected by tariff disputes and is taking big steps towards monetization. Yesterday, there was a strong price jump. Is a takeover coming soon? For example, BioNTech has full coffers and, as the latest IPO shows, is keen to invest in companies in the oncology sector.
Read
Commented by Armin Schulz on April 4th, 2025 | 07:10 CEST
Bayer's cancer drugs, Defence Therapeutics' cancer vaccine, Novo Nordisk's fat burner – Back on the road to success through specialization
The new trade tariffs threaten to destabilize the global supply chains of the pharmaceutical industry, increase the prices of generic drugs, and slow innovation cycles. The only winners in this environment will be those who focus on unique innovations to ensure resilience and growth. Bayer is trying to make itself fit for the future with an efficiency program, new pharmaceutical products, and digital agriculture platforms. Defence Therapeutics excels with precision-medicine cancer vaccines based on patented technology, opening up new markets. Novo Nordisk, in turn, is shaping a multibillion-dollar market with GLP-1 therapies for obesity and diabetes based on closed production cycles. These three approaches show how specialization and adaptability open new paths in turbulent times.
Read
Commented by André Will-Laudien on April 1st, 2025 | 07:20 CEST
Was that the Trump crash? Nevertheless, steeply upwards with Evotec, Bayer, BioNTech, Defence Therapeutics, or Valneva?
Since November 2024, Donald Trump has driven the markets sharply upward - his controversial new presidency was largely celebrated by investors. Now, his leadership feels somewhat unsettling, with fires seemingly being set again at every corner. The new president is acting more imperiously than ever, with Panama, Canada, and Greenland verbally on the agenda as the next US states. Meanwhile, the US administration is facing a considerable deficit, which is to be addressed by drastically reducing the size of the public sector and introducing tariffs. Unsurprisingly, interest rates are now rising sharply, which is a reason for weaker prices in the biotech sector. However, the sector has done its homework and is emerging from a three-year downturn. Are we now at buying levels?
Read
Commented by Fabian Lorenz on March 27th, 2025 | 07:00 CET
Rocketing prices and takeover speculation! Steyr Motors, Evotec, and Defence Therapeutics!
Steyr Motors is now riding not only the defense wave but also the takeover wave. After the announcement of a cooperation with a Rheinmetall subsidiary, the niche stock has become a shooting star. However, the price has also come back just as quickly. The Austrians now want to grow aggressively through acquisitions. Without takeover speculation, the share price of Defence Therapeutics has already risen by over 60%. The biotech company is still inexpensive, is making progress in monetization, and could become an acquisition candidate. Evotec is currently out of steam. Analysts see significant downside potential and a chance of a turnaround.
Read